SIRT1 Antibody

What is the expected molecular weight of SIRT1 protein in Western blotting?

While the calculated molecular weight of human SIRT1 is 82 kDa (747 amino acids), the observed molecular weight in SDS-PAGE typically ranges from 110-130 kDa (primary band) with some antibodies also detecting a band at 80-85 kDa . This discrepancy occurs due to posttranslational modifications, primarily glycosylation . When designing Western blot experiments, researchers should anticipate this higher molecular weight band and validate specificity using appropriate controls.

Which applications are validated for SIRT1 antibodies?

SIRT1 antibodies have been validated for multiple applications with specific dilution recommendations:

This data suggests broad utility of SIRT1 antibodies across common protein detection methods, with Western blotting being the most extensively validated application .

What is the subcellular localization pattern expected when using SIRT1 antibodies for immunofluorescence?

SIRT1 is predominantly localized to the nucleus. Immunofluorescence staining should show strong nuclear signal in most cell types . In rodent and human central nervous system tissues, SIRT1 immunoreactivity was observed throughout the brain parenchyma with predominantly nuclear staining . For immunofluorescence validation, cell lines such as HepG2 and HeLa have been confirmed to express detectable levels of SIRT1 . When conducting immunofluorescence, employ appropriate nuclear counterstains to confirm the expected nuclear localization pattern.

Which cell lines can serve as positive controls for SIRT1 antibody validation?

Several cell lines have been validated as positive controls for SIRT1 antibody testing:

• HEK-293 cells

• HeLa cells

• MDA-MB-231 cells

• HepG2 cells

• A172 (human glioblastoma)

• A549 (human lung carcinoma)

• CMSL0 cells

When validating a new SIRT1 antibody, include at least one of these established positive control cell lines to confirm specificity and expected banding pattern.

How do I address the discrepancy between predicted and observed molecular weights when validating SIRT1 antibodies?

The discrepancy between predicted (82 kDa) and observed (110-130 kDa) molecular weights for SIRT1 represents a common challenge in antibody validation. To systematically address this:

• Verify transcript variants: Different transcript variants can yield different protein sizes. In canine studies, SIRT1 variants 2 and 3 were primarily detected in PBMCs .

• Evaluate post-translational modifications: Glycosylation significantly contributes to the observed higher molecular weight. Consider using glycosylation inhibitors or deglycosylation enzymes to confirm this as the source of the molecular weight discrepancy.

• Implement SIRT1 knockdown/knockout controls: Include samples from cells with SIRT1 knockdown or knockout to confirm antibody specificity. Multiple publications have used KD/KO controls with SIRT1 antibodies .

• Compare multiple antibody clones: Different clones may preferentially recognize different forms of SIRT1. Running parallel blots with different antibodies can help confirm true SIRT1 signal.

The consistent detection of a higher molecular weight band across multiple studies and antibodies suggests this represents the authentic mature SIRT1 protein rather than non-specific binding .

What are the critical factors for successful SIRT1 detection in tissue immunohistochemistry?

Successful SIRT1 detection in tissue samples requires careful optimization of antigen retrieval methods:

• Antigen retrieval buffer selection: For optimal results with SIRT1 antibodies in IHC applications, use TE buffer pH 9.0 as the primary choice for antigen retrieval. Alternatively, citrate buffer pH 6.0 may be used but may yield different staining intensity .

• Fixation considerations: For central nervous system tissues, some studies avoided formaldehyde or glutaraldehyde fixation to minimize epitope modification, which significantly improved detection sensitivity .

• Incubation parameters: For challenging tissues, extended primary antibody incubation (up to 48 hours at 4°C) has been reported to enhance signal detection in brain and spinal cord sections .

• Antibody selection specificity: For human tissue samples, the rabbit monoclonal anti-SIRT1 antibody E104 has demonstrated significant association with consistent staining patterns in multiple studies .

• Validation controls: Include appropriate negative controls by replacing the primary SIRT1 antibody with serum to confirm the specificity of nuclear staining patterns .

How do species cross-reactivity issues affect SIRT1 antibody selection for comparative studies?

When conducting comparative studies across species, antibody cross-reactivity becomes a critical consideration:

• Documented cross-reactivity: Some SIRT1 antibodies demonstrate broad cross-reactivity. For example, monoclonal antibody 2G1/F7 shows consistent nuclear labeling patterns between rat and mouse brains without apparent species-dependent differences .

• Predicted versus verified reactivity: While computational predictions suggest potential reactivity with monkey, pig, and cat samples for some antibodies , experimental verification is essential before proceeding with valuable samples.

• Cited reactivity: Published literature has documented SIRT1 antibody reactivity with human, pig, chicken, zebrafish, bovine, sheep, goat, and megalobrama amblycephala samples .

• Confirmation methods: For unverified species, perform preliminary validation using Western blot of tissue lysates compared with a species with known reactivity. Look for consistent banding patterns and molecular weight shifts appropriate to species differences.

• Epitope conservation analysis: Consider the specific immunogen sequence used to generate the antibody (e.g., amino acids 581-630 of human SIRT1 or Ala2-Ser747 ) and compare sequence conservation across target species using sequence alignment tools.

What methodological approaches resolve contradictory findings in SIRT1 expression studies?

Meta-analyses of SIRT1 expression studies have revealed significant inconsistencies in results. To address these methodological challenges:

These methodological differences explain many contradictory findings in SIRT1 literature and suggest protocols for resolving such contradictions in future studies.

What are the validated protocols for detecting SIRT1 in peripheral blood mononuclear cells by flow cytometry?

Flow cytometry offers an alternative approach for SIRT1 detection in immune cells. Validated protocols include:

• Sample preparation: Isolate peripheral blood mononuclear cells (PBMCs) using density gradient centrifugation followed by cell surface marker staining if subpopulation analysis is desired.

• Fixation and permeabilization: Since SIRT1 is predominantly nuclear, effective nuclear permeabilization is critical for antibody access to the antigen.

• Antibody selection and validation: Prior to flow cytometry application, validate the SIRT1 antibody by Western blot using PBMCs to confirm the expected molecular weight bands.

• Transcript analysis: As a complementary validation approach, consider using inverse RT-PCR to identify which SIRT1 transcript variants are expressed in your specific cell population, as different variants may affect antibody binding .

• Controls: Include appropriate isotype controls and, where possible, SIRT1-knockdown samples to establish specificity of staining.

This approach enables high-throughput analysis of SIRT1 expression in individual cells within heterogeneous populations, providing advantages over bulk protein analysis methods.

How should researchers select SIRT1 antibodies for studies investigating specific functional domains?

SIRT1 contains multiple functional domains that mediate its diverse cellular functions. When investigating specific aspects of SIRT1 biology:

• Domain-specific antibodies: Select antibodies raised against specific domains based on your research question:

  • Sirtuin-type deacetylase domain (aa 241-495): Critical for enzymatic activity studies

  • Nuclear localization signals (aa 32-39 and 223-230): Important for nuclear transport studies

  • Nuclear export signal (aa 138-145): Relevant for nucleocytoplasmic shuttling studies

• Immunogen information assessment: Carefully review immunogen information for each antibody. For example, some antibodies target the C-terminal region (aa 581-630) while others target nearly the full-length protein (Ala2-Ser747) .

• Functional validation: Beyond detection validation, confirm the antibody's suitability for functional studies. For example, if studying deacetylase activity inhibition, verify the antibody doesn't interfere with the catalytic domain.

• Application-specific selection: Different experimental approaches may require different antibody characteristics:

  • For co-immunoprecipitation studies: Select antibodies validated for IP/CoIP applications

  • For chromatin studies: Use antibodies validated for ChIP applications

  • For interaction studies: Confirm the antibody epitope doesn't overlap with known protein-protein interaction domains

What methodological considerations are critical when using SIRT1 antibodies in chromatin studies?

SIRT1's role in chromatin regulation makes it an important target in epigenetic research. When using SIRT1 antibodies in chromatin studies:

• Cross-linking optimization: Since SIRT1 interacts with chromatin through protein-protein interactions rather than direct DNA binding, optimize formaldehyde cross-linking conditions to preserve these interactions.

• Antibody compatibility with fixed chromatin: Not all SIRT1 antibodies perform equally in chromatin immunoprecipitation. Verify the antibody has been validated specifically for ChIP applications.

• Epitope accessibility in chromatin context: Consider whether the antibody's epitope might be masked by chromatin interactions. C-terminal directed antibodies may offer advantages if the N-terminus is involved in protein-chromatin interactions.

• Controls for specificity: Include appropriate controls such as IgG controls and ideally SIRT1 knockdown/knockout samples to confirm specificity of chromatin binding patterns.

• Sequential ChIP considerations: For studies investigating SIRT1 co-occupancy with other factors, verify the SIRT1 antibody's compatibility with sequential ChIP protocols and that its elution conditions won't interfere with subsequent immunoprecipitation steps.

These methodological considerations are essential for generating reliable data on SIRT1's role in chromatin regulation and epigenetic modifications.

How can researchers address background and specificity issues when using SIRT1 antibodies?

Background and non-specific binding can significantly complicate SIRT1 detection. To improve signal-to-noise ratio:

• Blocking optimization: For Western blots, use 5% (w/v) nonfat dry milk in TBS-T as documented in successful protocols . For challenging samples, consider alternative blocking agents such as BSA or normal serum from the species of the secondary antibody.

• Antibody dilution titration: Systematically test a range of primary antibody dilutions. For Western blot, 1:1000-1:6000 has been validated; for IHC, 1:500-1:2000; and for IF/ICC, 1:200-1:800 .

• Incubation conditions: For Western blotting, overnight incubation at 4°C with antibody has shown good results in multiple studies . For tissues with lower expression, extended incubation (up to 48 hours at 4°C) may improve specific signal .

• Secondary antibody selection: Use highly cross-adsorbed secondary antibodies to minimize non-specific binding. For example, HRP-conjugated rabbit anti-mouse IgG (1:5,000) has been successfully employed for Western blotting .

• Detection system optimization: For challenging samples, high-sensitivity ECL systems such as ECL Prime have successfully detected SIRT1 in complex samples .

• Buffer optimization: Use PBS with 0.02% sodium azide and 50% glycerol pH 7.3 for antibody storage to maintain specificity over time .

What strategies can resolve inconsistent SIRT1 antibody performance across different tissue types?

Tissue-specific factors can significantly impact SIRT1 antibody performance. To address inconsistent results:

• Tissue-specific sample preparation: Different tissues may require modified extraction protocols to efficiently isolate SIRT1. For brain tissues, avoid formaldehyde or glutaraldehyde fixation to preserve epitope integrity .

• Antigen retrieval optimization: For IHC applications, TE buffer pH 9.0 is recommended as the primary choice, with citrate buffer pH 6.0 as an alternative . Systematically test both methods on your specific tissue type.

• Expression level considerations: SIRT1 expression varies significantly across tissues. In tissues with lower expression levels, signal amplification methods may be necessary.

• Isoform expression profiling: Different tissues may express different SIRT1 isoforms. Using inverse RT-PCR to identify dominant transcript variants in your tissue of interest can guide antibody selection and interpretation of Western blot banding patterns .

• Epitope masking assessment: Tissue-specific post-translational modifications or protein interactions may mask antibody epitopes. Testing multiple antibodies targeting different SIRT1 regions can help identify the most suitable antibody for each tissue type.